Lung microbiome dynamics in COPD exacerbations

Increasing evidence suggests that the lung microbiome plays an important role in chronic obstructive pulmonary disease (COPD) severity. However, the dynamics of the lung microbiome during COPD exacerbations and its potential role in disease aetiology remain poorly understood. We completed a longitudinal 16S ribosomal RNA survey of the lung microbiome on 476 sputum samples collected from 87 subjects with COPD at four visits defined as stable state, exacerbation, 2 weeks post-therapy and 6 weeks recovery. Our analysis revealed a dynamic lung microbiota where changes appeared to be associated with exacerbation events and indicative of specific exacerbation phenotypes. Antibiotic and steroid treatments appear to have differential effects on the lung microbiome. We depict a microbial interaction network for the lung microbiome and suggest that perturbation of a few bacterial operational taxonomic units, in particular Haemophilus spp., could greatly impact the overall microbial community structure. Furthermore, several serum and sputum biomarkers, in particular sputum interleukin-8, appear to be highly correlated with the structure and diversity of the microbiome. Our study furthers the understanding of lung microbiome dynamics in COPD patients and highlights its potential as a biomarker, and possibly a target, for future respiratory therapeutics. Lung microbiome changes are associated with COPD exacerbation events and implicated in host inflammatory responses http://ow.ly/Wamjx

[1]  Christopher E Brightling,et al.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.

[2]  Huiyun Zhang,et al.  Increased interleukin (IL)-8 and decreased IL-17 production in chronic obstructive pulmonary disease (COPD) provoked by cigarette smoke. , 2011, Cytokine.

[3]  J. Ruiz,et al.  Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. , 1995, American journal of respiratory and critical care medicine.

[4]  H. Boushey,et al.  Airway Microbiome Dynamics in Exacerbations of Chronic Obstructive Pulmonary Disease , 2014, Journal of Clinical Microbiology.

[5]  Paul Turner,et al.  Reagent and laboratory contamination can critically impact sequence-based microbiome analyses , 2014, BMC Biology.

[6]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[7]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[8]  S. Johnston,et al.  Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[9]  B. Tonelli [Chronic obstructive pulmonary emphysema]. , 1962, Gazzetta internazionale di medicina e chirurgia.

[10]  Rob Knight,et al.  UCHIME improves sensitivity and speed of chimera detection , 2011, Bioinform..

[11]  Eoin L. Brodie,et al.  Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB , 2006, Applied and Environmental Microbiology.

[12]  V. Pérez-Brocal,et al.  Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[13]  P. Ball Epidemiology and Treatment of Chronic Bronchitis and Its Exacerbations , 1995, Chest.

[14]  M. Briel,et al.  Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. , 2013, JAMA.

[15]  R. Rodríguez-Roisín,et al.  Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. , 1998, American journal of respiratory and critical care medicine.

[16]  M. Miravitlles,et al.  Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. , 1999, Chest.

[17]  C. Coban,et al.  Host innate immune receptors and beyond: making sense of microbial infections. , 2008, Cell host & microbe.

[18]  T. Seemungal,et al.  Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations , 2000, Thorax.

[19]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[20]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[21]  Pelin Yilmaz,et al.  The SILVA and “All-species Living Tree Project (LTP)” taxonomic frameworks , 2013, Nucleic Acids Res..

[22]  William A. Walters,et al.  QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.

[23]  K. Larsson Inflammatory markers in COPD , 2008, The clinical respiratory journal.

[24]  C. D. Mathers,et al.  Chronic obstructive pulmonary disease: current burden and future projections , 2006, European Respiratory Journal.

[25]  F. Martinez,et al.  The role of the microbiome in exacerbations of chronic lung diseases , 2014, The Lancet.

[26]  Charles K. Fisher,et al.  Identifying Keystone Species in the Human Gut Microbiome from Metagenomic Timeseries Using Sparse Linear Regression , 2014, PloS one.

[27]  Patrick M. Gillevet,et al.  Characterization of the Oral Fungal Microbiome (Mycobiome) in Healthy Individuals , 2010, PLoS pathogens.

[28]  V. Ivanova,et al.  IL-8 Regulates Mucin Gene Expression at the Posttranscriptional Level in Lung Epithelial Cells12 , 2009, The Journal of Immunology.

[29]  R. Greenblatt,et al.  Topographic diversity of the respiratory tract mycobiome and alteration in HIV and lung disease. , 2015, American journal of respiratory and critical care medicine.

[30]  O. Uzun,et al.  Role of bacteria in acute exacerbations of chronic obstructive pulmonary disease , 2008, International journal of chronic obstructive pulmonary disease.

[31]  J. Derisi,et al.  Pan-Viral Screening of Respiratory Tract Infections in Adults With and Without Asthma Reveals Unexpected Human Coronavirus and Human Rhinovirus Diversity , 2007, The Journal of infectious diseases.

[32]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[33]  T. Murphy,et al.  Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease , 2009, BMC infectious diseases.

[34]  C. Mcevoy,et al.  Adverse effects of corticosteroid therapy for COPD. A critical review. , 1997, Chest.

[35]  G. Rogers,et al.  Characterization of Bacterial Community Diversity in Cystic Fibrosis Lung Infections by Use of 16S Ribosomal DNA Terminal Restriction Fragment Length Polymorphism Profiling , 2004, Journal of Clinical Microbiology.

[36]  Curtis Huttenhower,et al.  Microbial Co-occurrence Relationships in the Human Microbiome , 2012, PLoS Comput. Biol..

[37]  F. C. Lowell,et al.  Chronic obstructive pulmonary emphysema; a disease of smokers. , 1956, Annals of internal medicine.

[38]  G. Hajishengallis,et al.  The keystone-pathogen hypothesis , 2012, Nature Reviews Microbiology.

[39]  Erik Johansson,et al.  Megavariate Analysis of Environmental QSAR Data. Part II – Investigating Very Complex Problem Formulations Using Hierarchical, Non-Linear and Batch-Wise Extensions of PCA and PLS , 2006, Molecular Diversity.

[40]  K. Chung,et al.  Cytokines in chronic obstructive pulmonary disease , 2001, European Respiratory Journal.

[41]  Robert C. Edgar,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2001 .

[42]  T. Murphy,et al.  Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review , 2001, Clinical Microbiology Reviews.

[43]  D. Postma,et al.  Airways inflammation and treatment during acute exacerbations of COPD , 2008, International journal of chronic obstructive pulmonary disease.

[44]  H. Dienemann,et al.  Analysis of the Airway Microbiota of Healthy Individuals and Patients with Chronic Obstructive Pulmonary Disease by T-RFLP and Clone Sequencing , 2013, PloS one.

[45]  I. Douglas,et al.  Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease? , 2006, Proceedings of the American Thoracic Society.

[46]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .